


## Barriers to Innovation: A Quality Perspective

Michael Kopcha, Ph.D., R.Ph.

Director
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

NASEM Virtual Workshop on Technical and Regulatory Barriers to Innovations in Pharmaceutical Manufacturing
June 2, 2020





#### **Pharmaceutical Quality**



A quality product of any kind consistently meets the expectations of the user.







#### **Pharmaceutical Quality**



A quality product of any kind consistently meets the expectations of the user.









Drugs are no different.



## Patients expect safe and effective medicine with every dose they take



### Pharmaceutical quality is

assuring *every* dose is safe and effective, free of contamination and defects



# It is what gives patients confidence in their *next* dose of medicine

#### **Topics**



- Regulating Pharmaceutical Quality
- The Importance of Advanced Manufacturing
- Barriers to Innovation
- Join Us in a Commitment to Quality






The Era of COVID-19

**Existing quality issues are** now magnified

Supply chains

Shortages

 Decision-making based on changing science and risk



#### A History of Quality Events









1938

1962

2015

2020?

Disruptions are perfect timing for innovations

We need a "better normal"

**Different** thinking is required

#### **CDER's Tools for Regulating Quality**



Inspection Assessment

**Engagement** 

Surveillance

Outreach

Patient Access Without Sacrificing Quality

**Enforcement** 

**Policy** 

**Testing** 

Research

#### Office of Pharmaceutical Quality



With a staff of ~1,300, OPQ's quality assessments


in a year are:

- Around 20 biologics
- Around 200 new drugs
- Around 3,000 investigational new drugs
- Around 4,000 generics
- Around 8,000 supplements



# The Importance of Advanced Manufacturing US FDA Center for Drug Evaluation and Research

#### The Shortage Issue





#### **Root causes for drug shortages:**

- Lack of incentives for manufacturers to produce less profitable drugs
- Market does not recognize and reward manufacturers for "mature quality systems"
- Logistical and regulatory challenges make it difficult to recover from a supply disruption


#### **Enduring solutions:**


- Understanding the impact of drug shortages and the contributing contracting practices
- A 'rating system' to incentivize quality management maturity
- Sustainable private sector contracts for a reliable supply of medically important drugs



#### What is Advanced Manufacturing?

- Novel manufacturing methods to improve process robustness and efficiency
- Novel dosage forms or delivery systems to improve drug delivery and targeting
- Novel analytical tools to improve product quality testing, process monitoring and/or control







## The Importance of Advanced Manufacturing for FDA & Industry



#### Addresses the underlying causes of drug shortages

- Mitigate or prevent future production problems
- COVID-19: Faster commercial production w/o scale-up issues

#### Facilitates new clinical modalities


- Precision and individualized medicines
- A wider range of novel dosage forms and doses
- Convenient fixed-combination dosage forms

#### Improves manufacturing efficiency

- Increase process robustness
- Lower manufacturing costs
- Increase supply chain flexibility











#### **Barriers from a Quality Perspective**



Regulatory

**Technical** 

**Financial** 

Logistical







## Operating within existing regulatory frameworks

- CGMPs
- Validation

#### Post-approval issues

- Inspecting new technologies
- Lifecycle management

#### International harmonization

Regulatory convergence needed





#### Inflexibility

- Lack of agile manufacturing operations
- Inflexible thinking & management

#### Inadequacy of analytical science

- Advanced Process Analytical Technology (PAT)
- Enable Real Time Release (RTR)





#### Capital required

- Grit!

#### Disruption required

 New thinking is required to address old and new problems





#### Training requirements

- Industry, operators
- Regulators, investigators
- Intellectual property
  - Process patents
- Lack of strategic partnering in industry
  - Will everyone come together to make this happen?







#### WE WANT YOU

**PAYORS PURCHASERS PROVIDERS STUDENTS COMPOUNDERS** 

REGULATORS

**PATIENTS CONSUMERS TEACHERS** MANUFACTURERS **PHARMACISTS HOSPITALS** 



#### What You Can Do


 Use this workshop to get to solutions, in a reasonable amount of time.

#### • Help us:

- Identify technologies we need to be prepared to see in applications in the next 5-10 years
- Address key technical and regulatory issues ahead of time
- Ensure these technologies deliver on the promise of a higher level of manufacturing quality
- Assure continued access to life-saving medicine for the U.S. public

#### **One Quality Voice for Patients**





We Are Patients, Too.

# Let's work together so we can ALL have confidence in our next dose of medicine

